January 12, 2026 a 12:38 pm
LLY: Analysts Ratings - Eli Lilly and Company
Eli Lilly and Company, a leader in the pharmaceutical industry, continues to show strong momentum with its diversified product portfolio. The current analyst sentiment reflects a positive outlook, with a dominant proportion of "Buy" recommendations. While there are some minor shifts towards more conservative ratings, the overall sentiment remains optimistic due to the ongoing developments and diverse collaborations within the company.
Historical Stock Grades
The historical data for Eli Lilly's stock shows a consistent trend towards "Buy" and "Hold" ratings, with minimal negative sentiment. Reviewing the latest data from January 2026, we find that:
| Type of Rating | Count | Score Bar |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 18 | |
| Hold | 7 | |
| Sell | 0 | |
| Strong Sell | 1 |
The data indicates a strong confidence from analysts, largely favoring "Buy" recommendations.
The chart above illustrates the historical trends of analyst ratings over time, supporting the insight of robust "Buy" support.
This stock chart visualizes Eli Lilly's stock price performance, reflecting the positive impact of analyst confidence on its market valuation.
Sentiment Development
- Over the past months, the number of "Buy" ratings has remained substantially higher than other ratings.
- There was a slight decrease in "Strong Buy" ratings, transitioning more into "Buy" and "Hold," suggesting a cautious optimism.
- The "Hold" category has shown a slight increase, indicating a balanced perspective among analysts.
This evolution reflects a cautious but generally positive sentiment towards Eli Lilly's prospects.
Percentage Trends
- The most significant shift is from "Strong Buy" to more moderate "Buy" and "Hold" ratings over the past six months.
- The proportion of "Buy" recommendations has stabilized, maintaining a large majority at nearly 72% as of January 2026.
- This suggests a robust confidence in the company's growth, albeit with a cautious shift as analysts watch for potential market volatilities.
Latest Analyst Recommendations
Recent analyst recommendations reflect stability in opinions, with most analysts maintaining their current ratings:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-12-15 | Buy | Buy | B of A Securities |
| 2025-12-10 | Overweight | Overweight | Wells Fargo |
| 2025-12-04 | Outperform | Outperform | BMO Capital |
| 2025-12-03 | Buy | Buy | Guggenheim |
| 2025-11-24 | Overweight | Overweight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
We see a mix of upgrades and downgrades, reflecting a nuanced view of the company's potential:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-11-10 | Hold | Buy | Freedom Capital Markets |
| 2025-11-10 | Outperform | Market Perform | Leerink Partners |
| 2025-09-17 | Hold | Buy | Berenberg |
| 2025-08-27 | Hold | Reduce | HSBC |
| 2025-04-28 | Reduce | Buy | HSBC |
Interpretation
The current sentiment among analysts towards Eli Lilly underscores a primarily positive outlook with a few signs of caution. Despite some downgrades, the majority of ratings remain in the "Buy" category, suggesting confidence in the company's strategic initiatives and market position. The combination of stable ratings and a reasonable number of upgrades reflects a balanced market perception without significant volatility. Generally, the analysts maintain a stable confidence in Eli Lilly's capability to sustain growth amid challenges.
Conclusion
In summary, Eli Lilly's stock has garnered strong "Buy" recommendations, showcasing a stable confidence in its market strategy and offerings. The slight shift towards "Hold" ratings may indicate cautious optimism, suggesting analysts are watching market dynamics closely. The balance of opinions reflects Eli Lilly’s solid positioning in a volatile sector. For investors, the company presents lucrative opportunities with accompanying risks, largely dependent on its continuous innovation and strategic partnerships. Ultimately, these insights highlight the importance of keeping abreast with market updates and potential industry shifts.